Chemistry:4-EA-NBOMe
From HandWiki
Short description: Substituted amphetamine designer drug
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H25NO |
| Molar mass | 283.415 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4-EA-NBOMe is a substituted amphetamine and 25-NB derivative which has been sold as a designer drug. It was first identified by a forensic laboratory in Germany in 2014,[1] but while its analytical properties and metabolism have been studied,[2][3][4] its pharmacology remains unknown.
See also
References
- ↑ "EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA". The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2015. http://www.emcdda.europa.eu/attachements.cfm/att_240380_EN_TDAN15001ENN.pdf.
- ↑ "Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs". Drug Testing and Analysis 8 (9): 910–9. September 2016. doi:10.1002/dta.1889. PMID 26606897.
- ↑ "LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques". Analytical and Bioanalytical Chemistry 410 (3): 897–912. January 2018. doi:10.1007/s00216-017-0526-0. PMID 28762065.
- ↑ "Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach". Toxicology Letters 285: 1–8. March 2018. doi:10.1016/j.toxlet.2017.12.017. PMID 29277574.
 |  |
